News
Multiple studies highlight pandemic’s impact on patients with rheumatic disease
From the Europe-based REUMAVID study to the United Kingdom’s CONTAIN study, some common themes are emerging, with lessons to be learned for future...
News
Baricitinib continuation rate high in real-world practice
Almost 75% of patients continued treatment at 6 months, and updated safety findings from the baricitinib clinical development program show no new...
News
Rituximab benefits seen in neuropsychiatric lupus
Findings from the largest prospective study of rituximab for NPSLE to date show signs of rituximab’s efficacy in reducing neuropsychiatric disease...
News
Line of therapy matters for assessing biologic’s serious infection risk in RA
The risk for serious infection seen with tocilizumab is confounded by whether the drug is given as first-line or as subsequent treatment in the...
News
Phage-targeting PCR test picks up early Lyme disease
Promising data show that detecting a viral gene in Lyme disease–causing bacteria can distinguish between early and late infection.
News
Hypofractionated radiotherapy: New normal for lung cancer?
Almost 20% of lung cancer patients in a U.K. study had their radiotherapy dose or fractionation schedule changed during the first wave of the...
News
Camrelizumab ‘another brick in the wall’ against squamous NSCLC
Adding camrelizumab to chemotherapy improved survival in patients with squamous non–small cell lung cancer.
News
Can benefits of SBRT outweigh risks in ultra-central lung tumors?
Stereotactic body radiotherapy for ultra-central lung tumors offers good disease control and survival but carries a risk of lung hemorrhage.
News
KRYSTAL-1: Clear activity of adagrasib in KRAS-mutated NSCLC
Phase 1/2 results with adagrasib confirm KRAS G12C as a druggable target in non–small cell lung cancer.
News
RA expert updates latest pathologic findings from Accelerating Medicines Partnership
Researchers have used single-cell analytic techniques to reveal pathologic RA synovial tissue differences in stromal and immune cells between...
News
No benefit seen with everolimus in early breast cancer
There were no improvements in survival when everolimus was added to hormone therapy.
News
OA risk-reduction program targets injured knees
The Stop Osteoarthritis program is currently testing the feasibility of a three-part intervention to help prevent posttraumatic knee OA.
News
Pandemic puts patients with psoriatic disease off seeking medical help
Both the physical and mental health of people with psoriasis and psoriatic arthritis has been affected by the ongoing COVID-19 pandemic.
News
Rheumatologic disease activity an important influencer of COVID-19 death risk
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from...
News
Entinostat doesn’t overcome endocrine resistance in advanced breast cancer
Phase 3 results do not support use of entinostat in advanced breast cancer.